Recipharm AB Appoints New Business Director For Italy And New General Manager At Pessac, France

Recipharm is pleased to announce the appointment of a new business director for the Italian pharmaceutical market and a new General Manager at Pessac, France.

Franco Boselli joins the Business Management team as Business Director in Italy with the main task to sell Recipharm's full service offering to Italian pharmaceutical companies . He reports to the Vice President of Business Management, Kenth Berg, and is based in Milan.

Prior to joining Recipharm, Mr Boselli worked in marketing and sales in different pharmaceutical companies in Italy. In 2009, he joined the B2B business as Business Development Manager in Mipharm, the Italian CMO, specialising in non-sterile products. In 2011, he joined Biologici Italia Laboratories, later part of the Corvette group acquired by Recipharm last year, as Business Development Director. In this role, he managed Corvette's key customers and was responsible for the scouting of new business, including the out-licensing of dossiers of sterile injectables and the development of new dossiers for generic products as well as sales of contract manufacturing of lyophilised and sterile formulations. Mr Boselli holds a degree in Economics from L. Bocconi University in Milan,

Bernard Pluta joins Recipharm as General Manager for the operating company in Pessac, France and will report to the Executive Vice President of Development and Technology, Carl- Johan Spak. Mr Pluta has had a long career in the pharma industry, having held executive positions in Theramex and Teva. He currently runs his own CMO consultancy business. Mr Pluta's primary task is to drive the performance at the company through the sales of new projects and operational excellence. He commenced his role on October 19th, replacing Stéphane Guisado who will continue in his role as General Manager in Recipharm Fontaine. Mr Pluta holds a master degree in Engineering from the French Grande Ecole of Arts & Métiers in Paris and an executive MBA from Ashridge Business School, UK.

Commenting on the appointments, Thomas Eldered, CEO of Recipharm said: "I am delighted that Mr Boselli and Mr Pluta have joined Recipharm. Both bring great skills and experience to our organization. Mr Boselli's knowledge and expertise will be invaluable to the continuing growth and expansion of our Italian business across the whole Recipharm network. Mr Pluta's industry expertise and solid business competence will play a key role in the task at hand to increase performance at Recipharm Pessac whilst maintaining the highest quality standards of service."

Contact information

Carl-Johan Spak, EVP Development & Technology, [email protected], +46 8 602 52 00

Kenth Berg, VP Business Management, [email protected], + 46 8 602 52 00

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: [email protected] or [email protected] or Tel: +44 (0) 203 735 8166

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.